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OBJECTIVES: The study objective was to examine the preva-
lence and factors associated with potential drug-drug interac-
tions on ACE Inhibitors prescription in the U.S. from
2001–2004. METHODS: This project proposed a secondary
data analysis using the U.S. National Ambulatory Medical Care
Survey (NAMCS) conducted by the National Center for Health
Statistics. A series of population weighted descriptive analyses
were performed to evaluate the prevalence of potential drug
interactions. Eisenberg’s sociologic theory was adopted to iden-
tify the potential patient and physician’s characteristics asso-
ciated with the presence of drug interactions. A weighted
multivariate logistic regression model was used to examine the
signiﬁcance of these predictor variables with 0.05 alpha level.
RESULTS: From 2001 to 2004, there were 125.6 million visits
where ACE inhibitors were prescribed for the treatment of
hypertension in the U.S., 48.1 million (38.3%) of these visits
encountered potential drug interactions. Signiﬁcant patient char-
acteristic included sex (OR = 1.57), pay type (OR =< 0.001),
region (OR = 2.41), age (P < 0.001), and number of medications
taken (P < 0.001). Signiﬁcant physician characteristics included
metropolitan region (OR = 0.22), ofﬁce setting (OR =< 0.001),
physician employment (OR =< 0.001), practice ownership (OR
=< 0.001), e-mail consultation (OR = 5.79), payment sources
(OR =< 0.001), and specialty; pediatrics (OR = 139.61), cardi-
ology (OR = 61.30), dermatology (OR =< 0.001), urology
(<0.001), and otolaryngology (OR =< 0.001). CONCLUSION:
The study reveals a very high prevalence rate (38.3%) and rec-
ognizes various patient and physician’s characteristics associated
with potential drug interactions with ACE Inhibitors. From the
public safety viewpoint, it is imperative for the interdisciplinary
health providers to identify new strategies to avoid drug inter-
actions, particularly for the patients with polypharmacy status.
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OBJECTIVES: Non-achievement of combined optimal lipid
values (OLVs) (LDL-C, HDL-C, and TG) is associated with 
an increased risk of cardiovascular events (CVE). Data compar-
ing combination lipid therapy effects on multiple lipid abnor-
malities and CVE reduction are limited. We modeled CVE risk
reduction with extended release niacin/simvastatin (ERN/S), sim-
vastatin/ezetimibe (S/E), extended release niacin (ERN), simvas-
tation (S), and ezetimibe (E), in a large managed care (MCO)
population. METHODS: Patients were selected from a 2.1
million record database if they had a lipid panel between January
1, 2000 and December 31, 2001, no concomitant lipid therapy,
and continuous eligibility for 24 months. Cardiovascular risk
and CVEs (determined by ICD-9/CPT codes, prescription
records, and ER visits/hospitalizations) for each patient were
identiﬁed, and OLV achievement was modeled using product
labeling at maximum doses (assuming additive effects for
ERN/S). Population CVE rate during 30 ± 12 months of follow-
up was 15.16% with an odds ratio 0.69 (CI: 0.61 to 0.81).
Achievement (18%) vs non-achievement (82%) of OLVs was uti-
lized to estimate CVE rates associated with modeled OLV
achievement rates. RESULTS: We analyzed 44,351 patients;
50% male, age 65 ± 13 years. Modeled lipid therapy resulted in
combined OLV achievement of: ERN/S 66.2%, S/E 48.4%, ERN
36.4%, S 46.3%, and E 18.4% (x2 p < 0.05 all vs baseline;
ERN/S vs S/E, ERN, and S; S/E vs S and E). Based upon achieve-
ment of OLV, the predicted population CVE rates were reduced
from baseline (15.16%) to: ERN/S 9.4 % (RRR: 38%), S/E
11.5% (RRR: 24%), ERN 13.0% (RRR: 14%), S 11.8% (RRR:
22%), and E 15.1% (RRR: 0.4%)(p < 0.05 for all except E vs
baseline; ERN/S vs S/E, ERN, and S; S/E vs E). CONCLUSION:
In this MCO population, OLVs were more frequently achieved
with ERN/S versus S/E, ERN, and S. Attaining combined OLVs
with combination ERN/S resulted in signiﬁcant reductions in
projected CVE rates.
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OBJECTIVES: To assess the current treatment of Acute Coro-
nary Syndromes in the hospital setting and determine whether
treatment would demonstrate comparable patterns around
Europe. METHODS: The IMS Acute Cardiovascular Analyzer
is an international database designed to track patients present-
ing with an ACS in Germany, France, Italy, Spain and UK.
RESULTS: A total of 8091 ACS cases were enrolled between
November 2005 and November 2006. Data were reported from
around 500 cardiologists. Baseline patient characteristics were:
female 32%, age over 65 years 43%, hypertension 68%, dys-
lipidemia 69%, diabetes 32%, obesity 29%, coronary artery
disease 12%. Most common treatments received in hospital
were: COX inhibitors 95%, Statins 86%, clopidogrel 79%, Beta-
blockers 72% and ACE inhibitors 69%. Thrombolytic agents
were administered to 32% of STEMI patients (68% in UK vs
7% in Germany) and 5% of them also received a primary PCI.
UA/NSTEMI patients had a PCI (50%) and mostly >12 hours
after onset of symptoms (66%). In Germany has the highest
number of PCIs performed within 12 hours after the acute event
(50%). Before hospital admission 25% of STEMI vs 38% of
NSTEMI/UA patients were on statins. Approximately 68% of
STEMI patients were discharged on clopidogrel and 81% on
statins. The in-hospital mortality rates were 8% (STEMI) vs 2%
(UA/NSTEMI). For the majority of the ACS patients (55%) the
length of stay in hospital was 5–10 days. CONCLUSION: These
data can be used to identify key factors determining therapeutic
decision making concerning ACS treatment in Europe.
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OBJECTIVES: Is it enough to check for statistical heterogeneity
before plunging into a meta-analysis? For example, there are
many clinical trials of rhythm control drugs for atrial ﬁbrillation
(AF), suggesting a meta-analysis is the way to go. Is it?
METHODS: A MEDLINE search yielded 347 studies, of which
20 met strict inclusion criteria. Only randomized, blinded studies
of adults with ECG-conﬁrmed AF or atrial ﬂutter recurrence
were considered. Studies had to compare antiarrhythmic agents
or antiarrhythmics with placebo. Crossover studies and studies
of AF after cardiac surgery were excluded. RESULTS: After
detailed review, we decided that, in contrast with a published
systematic review, meta-analysis was not appropriate due to
intractable heterogeneity in study designs. Although recurrence
risk differs substantially between chronic and paroxysmal AF,
